Cardiac Mapping Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Cardiac Mapping Market is Segmented by Type (Contact Cardiac Mapping Systems and Non-Contact Cardiac Mapping Systems), Indication (Atrial Fibrillation, Atrial Flutter, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report offers the value (USD million) for the above segments.

Market Snapshot

Cardiac Mapping Market Overview
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 8.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The cardiac mapping market is projected to register a CAGR of 8.5% during the forecast period (2022 - 2027).

The COVID-19 pandemic harmed the cardiac mapping market. Various research studies have been published to provide insight into the impact of the pandemic on the market. For instance, in January 2021, a research study published titled "Cardiac Involvement of COVID-19: A Comprehensive Review" stated that COVID-19 can significantly affect patients' cardiovascular systems. Mortality from COVID-19 is strongly associated with cardiovascular disease, diabetes, and hypertension. Hence, patients suffering from CVDs must take more precautions against COVID-19, which may require the adoption of cardiac mapping.

Similarly, in September 2020, another research study published titled "Impact of COVID-19 on the Cardiovascular System: A Review of Available Reports" stated there is an increase in morbidity and mortality in patients suffering from both cardiovascular complications and COVID-19. Therefore, more considerable attention is needed to viral infection-related heart damage during treatment. With such studies, the market is likely to increase as it provides the need for cardiac mapping due to the COVID-19 pandemic.

Cardiovascular diseases (CVDs) affect the heart and blood vessels of the body. These diseases affect one or more than one parts of the heart and blood vessels. Patients suffering from CVDs can be symptomatic or asymptomatic. As per the 2021 update by the World Health Organization (WHO), CVDs include coronary heart disease, cerebrovascular disease, rheumatic heart disease, and other conditions. The same source also reports that cardiovascular diseases (CVDs) are the leading cause of death globally, and an estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. Of these deaths, 85% were due to heart attack and stroke. In addition, the source mentioned above also reports that out of the 17 million premature deaths (under the age of 70) due to noncommunicable diseases in 2019, 38% were caused by CVDs and more than three-quarters of CVDs deaths take place in low-and middle-income countries. As per the Journal of Cardiovascular Development and Disease article titled 'Cardiovascular Risks Associated with Gender and Aging' published in April 2019, reported by the American Heart Association (AHA) 2019 Heart Disease and Stroke Statistical Update, the incidence of cardiovascular diseases from age 60–79 years was reported to be 77.2% in males and 78.2% in females.

Furthermore, the incidence of CVD in adults above 80 years of age was reported to be 89.3% in males and 91.8% in females. Therefore, the high prevalence of cardiac disease in older age drives the market's growth. Thus, the rising prevalence of cardiovascular diseases is driving the growth of the market studied.

Factors such as product launches and approvals are key for the growth of the market in the upcoming future. In August 2020, Biosense Webster launched the latest Carto heart mapping system generation. The Carto Prime mapping module adds tools to the Carto 3 platform for further addressing all major complex arrhythmias, with improvements in mapping capabilities that help to reduce ablation times compared to standard mapping algorithms. With such launches, the market is likely to grow in the upcoming future. Product approvals are another factor in the growth of the market. In November 2020, Abbott received CE Mark and approval in Australia for its new EnSite X EP System, launching it throughout Europe and Australia. The EnSite X System is the only system that offers the option to navigate the cardiac anatomy in two different ways on one platform. The EnSite X System has advanced imaging capabilities that create a three-dimensional (3D) model of the patient's cardiac anatomy in real-time, allowing physicians to see areas of the heart that need ablation treatment. With such approvals, the market is likely to grow in the future.

However, the lack of skilled electrophysiologists will likely hinder the market's growth.

Scope of the Report

As per the scope, cardiac mapping is an electrophysiology study to understand the cause of heart rhythm problems like arrhythmia. Mapping the electrical activity of the heart is a critical component for diagnosing and treating heart disease. The Cardiac Mapping Market is Segmented by Type (Contact Cardiac Mapping Systems and Non-Contact Cardiac Mapping Systems), Indication (Atrial Fibrillation, Atrial Flutter, and Others), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD million) for the above segments.

By Type
Contact Cardiac Mapping Systems
Non-Contact Cardiac Mapping Systems
Atrial Fibrillation
Atrial Flutter
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Atrial Fibrillation Segment is Expected to Hold a Significant Market Share Over the Forecast Period

Factors such as increasing atrial fibrillation, research studies, and initiatives are expected to drive the growth of the segment in the upcoming future. According to the Centers for Disease Control and Prevention, in 2019, in the United States, AFib was responsible for 183,321 death and was the underlying cause of death in 26,535 of those cases. The same source stated that more than 454,000 hospitalizations with AFib as the primary diagnosis happen each year in the United States. The condition contributes to about 158,000 deaths each year. It is estimated that 12.1 million people in the United States will have atrial fibrillation (AFib) in 2030. Similarly, the International Journal of Stroke article titled “National trends in hospital admission, case fatality, and sex differences in atrial fibrillation-related strokes,” published in October 2019, reported that Atrial fibrillation is present in an increasing proportion of people hospitalized in Canada and disproportionately affects older women.

Moreover, in June 2021, Cardiac Insights, Inc., a United States-based healthcare innovator specializing in wearable cardiac sensors and proprietary software that automatically analyzes electrocardiogram (ECG) data to improve early detection and diagnosis of cardiac arrhythmias, such as atrial fibrillation (Afib) announced launching its Cardea SOLO ECG System at Arab Health 2021, the largest healthcare exhibition in the Middle East. In August 2020, Boston Scientific developed the LUX-Dx implantable cardiac monitoring (ICM) system for the long-term diagnosis of arrhythmias associated with conditions such as atrial fibrillation and syncope. Boston Scientific filed its 510(k) submission for the LUX-Dx with the US Food and Drug Administration (FDA) in December 2019. It received clearance for commercialization in the US under the Class II medical device category in June 2020.

Hence, the abovementioned factors will likely increase market growth in the future.

Cardiac Mapping Market Growth

North America is Expected to Dominate the Market Over the Forecast Period

With the rising focus on patient care and need, supported by the well-developed infrastructure and technologically advanced healthcare system, the increasing burden of cardiac diseases and rising geriatric population is expected to drive the market growth in the region. According to the American Heart Association, statistics published in January 2019 report that nearly half of Americans have some kind of cardiovascular disease, including hypertension, coronary heart disease, etc. As cardiac mapping devices are used for properly diagnosing and treating cardiac diseases, the prevalence of cardiac diseases is expected to boost the market's growth. Also, according to the Centres for Disease Control and Prevention (CDC), in September 2020, heart disease was the leading cause of death in the United States. Every year, about 805,000 Americans have a heart attack. As the number of deaths due to heart diseases increases, there is a growing demand for the proper detection and diagnosis of cardiac diseases and mapping devices to fulfill the unmet needs. Hence are expected to show growth over the forecast period. According to the Heart and Stroke Foundation of Canada's Report 2019 titled "(Dis)connected: How unseen links are putting us at risk," in Canada, one person dies every five minutes from heart conditions, stroke, or vascular cognitive impairment. The same source also reports that 90% of people in Canada have at least one risk factor for heart conditions, stroke, or vascular cognitive impairment. This increased risk among the Canadian population is driving the market's growth. Also, the International Journal of Environmental Research and Public Health article titled 'Attributable Burden and Expenditure of Cardiovascular Diseases and Associated Risk Factors in Mexico and other Selected Mega-Countries,' published in October 2019, reported that public health implications are evident considering that CVD currently generates significant health and economic burden in Mexico.

Hence, the market is likely to grow due to the abovementioned factors.

Cardiac Mapping Market Analysis

Competitive Landscape

The market is partially fragmented and consists of several major players. Biosense Webster, Inc., Abbott Laboratories, Medtronic Plc, Boston Scientific Corporation, and Acutus Medical are currently dominating the market.

Recent Developments

· In January 2022, Medtronic PLC, a global leader in healthcare technology, announced that it had entered into a definitive agreement to acquire Affera, Inc., a Boston area-based, privately held medical technology company, at USD 925 million. After designing and manufacturing cardiac mapping and navigation systems and catheter-based cardiac ablation technologies, including a differentiated, focal pulsed-field ablation solution, for treating patients with cardiac arrhythmias (irregular heartbeats) such as atrial fibrillation (AF).

· In January 2022, Abbott received FDA clearance for its EnSite X EP with EnSite Omnipolar technology (OT). EnSite X EP creates highly detailed three-dimensional heart maps to help physicians identify and treat areas where abnormal rhythms originate.

Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Incidence of Target Diseases and Geriatric Population

      2. 4.2.2 Growing Investments, Funds, and Grants

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Skilled and Experienced Electrophysiologists

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value – USD million)

    1. 5.1 By Type

      1. 5.1.1 Contact Cardiac Mapping Systems

      2. 5.1.2 Non-Contact Cardiac Mapping Systems

    2. 5.2 Indication

      1. 5.2.1 Atrial Fibrillation

      2. 5.2.2 Atrial Flutter

      3. 5.2.3 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 Acutus Medical

      3. 6.1.3 Angiodynamics

      4. 6.1.4 APN Health, LLC

      5. 6.1.5 Biosense Webster, Inc.

      6. 6.1.6 Biosig Technologies, Inc.

      7. 6.1.7 Boston Scientific Corporation

      8. 6.1.8 Kardium, Inc.

      9. 6.1.9 Koninklijke Philips N.V.

      10. 6.1.10 Lepu Medical

      11. 6.1.11 Medtronic Plc

      12. 6.1.12 Microport Scientific Corporation

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Cardiac Mapping Market market is studied from 2019 - 2027.

The Global Cardiac Mapping Market is growing at a CAGR of 8.5% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Biosense Webster, Inc. (A Johnson & Johnson Company), Abbott Laboratories, Medtronic Plc, Boston Scientific Corporation, Acutus Medical are the major companies operating in Global Cardiac Mapping Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!